



10-17-06

AF  
[initials]

PATENT  
Customer No. 22,852  
Attorney Docket No. 03495.194-01  
Express Mail Label No.: EV 799294695 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Penelope MAVROMARA et al.	)	Group Art Unit: 1636
	)	
Application No.: 10/664,038	)	Examiner: James S. Ketter
	)	
Filed: September 17, 2003	)	
	)	
For: NUCLEIC ACIDS AND NEW	)	Confirmation No.: 3906
POLYPEPTIDES ASSOCIATED WITH	)	
AND/OR OVERLAPPING WITH	)	
HEPATITIS C VIRUS CORE GENE	)	
PRODUCTS	)	

**CERTIFICATE UNDER 37 CFR § 1.10 OF  
MAILING BY "EXPRESS MAIL"**

EV 799294695 US  
USPS Express Mail Label Number

October 16, 2006  
Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Sherleen Goodlette  
Sherleen Goodlette

Attachments:

1. Amendment After Final (8 pages)
2. Post Card to Acknowledge Receipt



**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1636  
PATENT**

Attorney Docket No. 03495.0194-01  
Express Mail Label No.: EV 799294695 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Penelope MAVROMARA et al.	)	Group Art Unit: 1636
	)	
Application No.: 10/664,038	)	Examiner: James S. Ketter
	)	
Filed: September 17, 2003	)	
	)	
For: NUCLEIC ACIDS AND NEW	)	Confirmation No.: 3906
POLYPEPTIDES ASSOCIATED	)	
WITH AND/OR OVERLAPPING	)	
WITH HEPATITIS C VIRUS CORE	)	
GENE PRODUCTS	)	

Mail Stop AF  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT AFTER FINAL**

In reply to the Final Office Action mailed July 14, 2006, and pursuant to 37 C.F.R.

§ 1.116, Applicants propose that this application be amended as follows:

**Amendments to the Specification** are included in this paper at page 2.

**Amendments to the Claims** are reflected in the listing of claims in this paper,  
beginning on page 3.

**Remarks/Arguments** follow the amendment sections of this paper, beginning on  
page 5.